Cullinan Q2 FY26 net loss narrows 23.36% to $53.7 million - CGEM News | RalliesCullinan Q2 FY26 net loss narrows 23.36% to $53.7 million
C
CGEM• Pipeline updates and upcoming readouts
- CLN-049 potentially registrational Phase 2 study in relapsed/refractory AML is set to start in Q3 2026, following an End-of-Phase 1 FDA meeting.
- Nadim Ahmed said the company expects additional 2026 clinical data readouts for CLN-978 and velinotamig as programs advance toward Phase 2.
Second-quarter loss narrows as expenses decline
- Cullinan Therapeutics posted a Q2 net loss of USD 53.7 million, narrowing from USD 70.1 million a year earlier.
- R&D expense fell to USD 44.4 million from USD 61 million, while G&A expense dropped to USD 12.8 million from USD 14.8 million.
- Cash, cash equivalents, investments, and interest receivable totaled USD 356 million at June 30, 2026; runway expected into 2029.
•
